One in eight Americans has used a GLP-1 medicine like Ozempic, food-industry report says

About 12% of Americans — roughly 41 million people — have used a GLP-1 medicine, and about 20 million are taking one now, according to industry analysis cited in a food-industry report published Oct. 20, 2025 ^[1]. That works out to about one in eight people in the country.

The same report also leads with a narrower figure: 6% of Americans are currently taking a GLP-1 drug. It adds that this number "could be wildly underestimated" ^[1]. The two figures describe different things — ever used versus taking one now — and the article does not explain how either was measured or who collected the underlying data. GLP-1 medicines include semaglutide, sold as Ozempic, Wegovy and Rybelsus, and tirzepatide, sold as Mounjaro and Zepbound ^[1].

The article frames the trend as a "once-in-a-generation opportunity – or risk being left behind" for food businesses as use of weight-loss medications surges and new therapies emerge ^[1]. Food and beverage companies have begun reformulating around smaller portions as users report eating far less ^[1]. Reporting published by the same outlet on Oct. 15, 2025 describes rapid growth in a GLP-1 food and beverage sector, along with rising risks and costs ^[1].

Nutrition has become part of the story. An article from the same publication dated Aug. 19, 2025 says GLP-1 users can be undernourished and frames nutrient gaps in their diets as both a challenge and an opportunity for the food industry ^[1]. Another, dated Sept. 6, 2025, says the drugs' effects on gut health are raising questions ^[1]. The reporting does not give specific products, reformulation dates or sales numbers for any of these items.

Why it matters for patients

The size of the GLP-1 population shapes everyday choices. If roughly one in eight Americans has used one of these medicines ^[1], patients are likely to encounter more food products built for smaller appetites — single-serve packs, downsized portions and protein-focused items — rather than the larger formats common on shelves today.

Those changes cut two ways. Eating far less can also mean taking in fewer vitamins, minerals and protein, and the reporting flags undernourishment among GLP-1 users ^[1]. How common that is, which nutrients are most often short, and whether reformulated foods close the gap have not been reported.

The estimates themselves carry uncertainty. They come from industry analysis cited in the article, not from a published survey with disclosed methods, and the article does not say how the 41 million and 20 million figures were calculated ^[1]. It also does not break out how many people use these medicines for type 2 diabetes versus obesity.

What happens next

No product launch dates, clinical trial results or regulatory decisions are given in the reporting. The most recent GLP-1 food-industry item cited is dated Oct. 15, 2025 ^[1]. Whether smaller portions and new formulations change what patients eat, or their nutrient intake, has not been reported.